Time to Reconsider Bioverativ Inc. (BIVV) After Making 52-Week High?

January 13, 2018 - By Adrian Erickson

The stock of Bioverativ Inc. (NASDAQ:BIVV) hit a new 52-week high and has $65.66 target or 3.00 % above today’s $63.75 share price. The 9 months bullish chart indicates low risk for the $6.90B company. The 1-year high was reported on Jan, 13 by Barchart.com. If the $65.66 price target is reached, the company will be worth $206.94 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 1.66% or $1.04 during the last trading session, reaching $63.75. About 1.56M shares traded or 25.90% up from the average. Bioverativ Inc. (NASDAQ:BIVV) has 0.00% since January 13, 2017 and is . It has underperformed by 16.70% the S&P500.

Analysts await Bioverativ Inc. (NASDAQ:BIVV) to report earnings on January, 25. BIVV’s profit will be $51.94 million for 33.20 P/E if the $0.48 EPS becomes a reality. After $0.63 actual EPS reported by Bioverativ Inc. for the previous quarter, Wall Street now forecasts -23.81 % negative EPS growth.

Bioverativ Inc. (NASDAQ:BIVV) Ratings Coverage

Among 2 analysts covering Bioverativ (NASDAQ:BIVV), 1 have Buy rating, 1 Sell and 0 Hold. Therefore 50% are positive. Bioverativ had 2 analyst reports since February 2, 2017 according to SRatingsIntel. The firm has “Underweight” rating given on Thursday, February 2 by Morgan Stanley. The rating was initiated by Gabelli on Thursday, February 2 with “Buy”.

More news for Bioverativ Inc. (NASDAQ:BIVV) were recently published by: Streetinsider.com, which released: “Bioverativ Inc (BIVV) PT Raised to $100 at Cowen” on January 09, 2018. Businesswire.com‘s article titled: “Bioverativ Announces 2018 Annual Meeting of Stockholders” and published on December 22, 2017 is yet another important article.

Bioverativ Inc., a biotechnology company, focuses on the research, discovery, development, and commercialization of therapies for the treatment of hemophilia and other blood disorders in the United States and Japan. The company has market cap of $6.90 billion. The firm offers ELOCTATE, an antihemophilic factor Fc fusion protein; and ALPROLIX, a coagulation factor IX (Recombinant) Fc fusion protein for the treatment of hemophilia A and B. It has a 15.56 P/E ratio. It is also developing BIVV 001 (rFVIIIFc-VWF-XTEN), a preclinical program of the combination of factor VIII-Fc fusion protein for the treatment of hemophilia A; BIVV 002 (rFIXFc-XTEN), a preclinical program for a recombinant factor IX replacement product for the treatment of patients with hemophilia B; and Bi-Specific antibody program, a preclinical program to develop a non-factor bi-specific antibody for the treatment of patients with hemophilia A.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.